The Churg–Strauss Syndrome after Pranlukast Treatment in a Patient Not Receiving Corticosteroids
Authors: Takashi Katsura
Journal: Annals of Internal Medicine (2003)

Letters2 September 2003The Churg–Strauss Syndrome after Pranlukast Treatment in a Patient Not Receiving CorticosteroidsTakashi Katsura, MD, Fumihide Yoshida, MD, and Yasutaka Takinishi, MDTakashi Katsura, MDFrom Showa University Toyosu Hospital; Tokyo, 135-8577 Japan.Search for more papers by this author, Fumihide Yoshida, MDFrom Showa University Toyosu Hospital; Tokyo, 135-8577 Japan.Search for more papers by this author, and Yasutaka Takinishi, MDFrom Showa University Toyosu Hospital; Tokyo, 135-8577 Japan.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The Churg–Strauss syndrome is a disorder characterized by eosinophilic inflammation and necrotizing vasculitis associated with asthma and blood eosinophilia (1). Since Wechsler and colleagues (2) reported the case series in 1998, there have been case reports of the syndrome after the administration of leukotriene receptor antagonists. Investigators have suggested that the patients with the Churg–Strauss syndrome were identified after corticosteroid withdrawal (3, 4). However, there have been reports of patients with the Churg–Strauss syndrome associated with zafirlukast and with montelukast who had never received corticosteroid therapy (5, 6). We report a case of the Churg–Strauss syndrome that ...References1. Schoen FD, Cotran RS. Blood vessels.. In: Cotran RS, Kumar V, Collins T, eds. Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders; 1999:493-541. Google Scholar2. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, . Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279:455-7. [PMID: 9466639] CrossrefMedlineGoogle Scholar3. Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, . Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117:708-13. [PMID: 10712995] CrossrefMedlineGoogle Scholar4. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol. 2001;14:1284-93. [PMID: 11743052] CrossrefMedlineGoogle Scholar5. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment [Letter]. Lancet. 1999;353:725-6. [PMID: 10073523] CrossrefMedlineGoogle Scholar6. Sabio JM, Jimenez-Alonso J, Gonzalez-Crespo F. More about Churg-Strauss syndrome and montelukast treatment [Letter]. Chest. 2001;120:2116. [PMID: 11742954] CrossrefMedlineGoogle Scholar7. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax. 1997;52:523-7. [PMID: 9227718] CrossrefMedlineGoogle Scholar8. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, . The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-100. [PMID: 2202307] CrossrefMedlineGoogle Scholar9. Jamaleddine G, Diab K, Tabbarah Z, Tawil A, Arayssi T. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum. 2002;31:218-27. [PMID: 11836655] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Showa University Toyosu Hospital; Tokyo, 135-8577 Japan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIdiopathic interstitial pneumonias and immunologic diseases of the lungsA Case of Churg-Strauss Syndrome Following Corticosteroid WithdrawalSmall-vessel and medium-vessel vasculitisCysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trendsResponsabilité des antileucotriènes dans la survenue d'un syndrome de Churg et StraussThe linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?Churg-Strauss Syndrome and Leukotriene-Modifying Agents 2 September 2003Volume 139, Issue 5_Part_1Page: 386-387KeywordsAsthmaBiopsyCorticosteroid therapyDiarrheaEosinophiliaEosinophilsFeversLeukotrieneOutpatient clinicsReceptor antagonist therapy ePublished: 2 September 2003 Issue Published: 2 September 2003 CopyrightCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...